Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma
Status:
Completed
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if certain features of tumor specimens sampled
prior to therapy can predict for the likelihood of responding to everolimus.
Phase:
Phase 2
Details
Lead Sponsor:
Beth Israel Deaconess Medical Center Dana-Farber Cancer Institute
Collaborators:
Dana-Farber Cancer Institute Duke University Novartis